APAC Healthcare Weekly (June 15)- CSPC, Wuxi Bio, Samsung Bio, Daiichi Sankyo, SanBio, Cochlear

495 Views15 Jun 2025 08:30

CSPC entered research collaboration with AstraZeneca. Wuxi Bio is constructing new plant in China. Samsung Bio signed new CDMO contract. Daiichi Sankyo initiates Phase 3 trial of Enhertu.

What is covered in the Full Insight:

CSPC and AstraZeneca Collaboration
Wuxi Biologics New Manufacturing Site
Samsung Biologics CDMO Contract
Daiichi Sankyo Phase 3 Trial
Cochlear Introduces Nucleus Nexa

Tina Banerjee

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 5-minute read)

Discussions

(Paid Plans Only)

Insight Stream